News and views for the UB community
Q&A
By ELLEN GOLDBAUM
Published August 28, 2024
A UB neuroscientist whose focus is the brain’s reward system and its role in addiction is helping to illuminate how exercise can aid the brain in addiction recovery. Over the past year, this research has revealed that because exercise acts on the same areas of the brain that addiction does, it has the potential to become an important treatment tool for people with substance use disorder.
Panayotis “Peter” K. Thanos, senior research scientist in the Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences at UB, is a lead or senior author on publications that describe his work that ranges from looking at sex differences in addiction and exercise in Clinics and Practice to how exercise can address alcohol use disorder in Psychology Research and Behavior Management.
Thanos, who also is director of the Behavioral Neuropharmacology and Neuroimaging Laboratory in UB’s Clinical and Research Institute on Addictions, spoke with UBNow about the potential of exercise as a treatment for substance use disorders.
About 15 years ago I became aware of several recovery running programs in New York City and Philadelphia that were showing improved success in maintaining sobriety and reduced risk for relapse. This led me to look into the mechanism of this clinical observation using animal models. The first results from this research were very supportive of the potential of exercise in curbing drug preference as a powerful adjunct tool to aid in recovery and to reduce the risk of relapse.
The effects of exercise must be better characterized and understood. For instance, we don’t yet understand the complexities of exercise and the individual differences in response to different types of exercise regimens. We also don’t yet fully understand the concept of exercise dose: How much exercise is needed to have the desired effect? All exercise is not created equal and does not yield the same effects on all people in terms of brain signaling and behavior.
Yes, in collaboration with Western University of Health Sciences, we are involved in clinical research to assess exercise dose and relapse risk. We hope to have some pilot data by next spring that we will use to apply for NIH (National Institutes of Health) funding. In preclinical research, we are looking at how exercise impacts endocannabinoid brain signaling, as well as brain functional connectivity.
More research on understanding exercise dose and regimens is needed. We cannot generalize and say that all exercise is the same in order to properly assess its impact in medicine. We must also better understand how exercise is impacted by our individual genomic differences, similar to what we know happens with pharmacogenomics. Funding more research to better understand how exercise could be applied in medicine will provide tremendous opportunity to improve public health.